Skip to main content
    B

    Bicycle Therapeutics Ltd (BCYC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.20
    +0.02 (+0.63%)

    Market Cap: $222.90M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Bicycle Therapeutics Ltd (BCYC) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Bicycle Therapeutics (BCYC) trades at 2.7x sales and 0.4x book value. Its P/S of 2.7x is below its 5-year median of 25.2x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/EN/A
    Price to sales2.7x
    Price to book0.4x
    PEGN/A
    FCF yield-78.9%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S2.7x25.2xN/A
    P/B0.4x1.6xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 7 year ends shown, its P/S ranged from 6.8x in 2025 to 132.3x in 2021. 2025 was the lowest of those years.

    Year endPriceP/SP/B
    2025$7.086.8x0.8x
    2024$14.0019.1x1.2x
    2023$18.0822.6x2.1x
    2022$29.6060.7x3.2x
    2021$60.87132.3x5.1x
    2020$17.9533.9x4.0x
    2019$9.4310.5x1.8x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About BCYC

    What is BCYC's price to sales ratio?

    Bicycle Therapeutics has a price to sales ratio of 2.7x.